BACKGROUND: Transcatheter aortic valve implantation (TAVI) is known to be associated with silent cerebral injury, which could contribute to cognitive impairment. Considering its increasing use, thorough longitudinal investigation of cognitive trajectory after TAVI is pivotal. METHODS AND RESULTS: Repeatable battery for the assessment of neuropsychological status was performed before (E1), 3 days (E2), 3 months (E3), 1 (E4) year, and 2 years (E5) after TAVI. Baseline characteristics, procedural data, imaging parameters of brain injury (diffusion-weighted MRI), and the use of conceivable neuroprotective approaches were investigated for their effect on cognitive function. Cognitive performance was investigated in 111 patients (mean log EuroSCORE, 30±13%). Global cognitive function (repeatable battery for the assessment of neuropsychological status total score) increased transiently at E2 (P=0.02) and was comparable with baseline levels at E3, E4, and E5. Six patients (5.4%) demonstrated early cognitive decline. Persistence and late onset were seen infrequently (n=3, 2.7% and n=4, 3.6%, respectively). Hence, early cognitive decline was ruled out in 105 patients (94.6%), and a majority of patients (91%) demonstrated sustained cognitive performance throughout all investigated time points. Interestingly, only patient age (P=0.012), but not prior cerebrovascular events, cognitive status, direct TAVI, cerebral embolism in diffusion-weighted MRI, or the use of a cerebral embolic protection device was found to be independently associated with cognitive decline, linking higher age to cognitive impairment along the first 2 years after TAVI. CONCLUSIONS: Long-term cognitive performance was preserved in the great majority (91%) of patients throughout the first 2 years after TAVI, despite the high intrinsic risk for cognitive deterioration. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00883285.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is known to be associated with silent cerebral injury, which could contribute to cognitive impairment. Considering its increasing use, thorough longitudinal investigation of cognitive trajectory after TAVI is pivotal. METHODS AND RESULTS: Repeatable battery for the assessment of neuropsychological status was performed before (E1), 3 days (E2), 3 months (E3), 1 (E4) year, and 2 years (E5) after TAVI. Baseline characteristics, procedural data, imaging parameters of brain injury (diffusion-weighted MRI), and the use of conceivable neuroprotective approaches were investigated for their effect on cognitive function. Cognitive performance was investigated in 111 patients (mean log EuroSCORE, 30±13%). Global cognitive function (repeatable battery for the assessment of neuropsychological status total score) increased transiently at E2 (P=0.02) and was comparable with baseline levels at E3, E4, and E5. Six patients (5.4%) demonstrated early cognitive decline. Persistence and late onset were seen infrequently (n=3, 2.7% and n=4, 3.6%, respectively). Hence, early cognitive decline was ruled out in 105 patients (94.6%), and a majority of patients (91%) demonstrated sustained cognitive performance throughout all investigated time points. Interestingly, only patient age (P=0.012), but not prior cerebrovascular events, cognitive status, direct TAVI, cerebral embolism in diffusion-weighted MRI, or the use of a cerebral embolic protection device was found to be independently associated with cognitive decline, linking higher age to cognitive impairment along the first 2 years after TAVI. CONCLUSIONS: Long-term cognitive performance was preserved in the great majority (91%) of patients throughout the first 2 years after TAVI, despite the high intrinsic risk for cognitive deterioration. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00883285.
Authors: Pál Maurovich-Horvat; Béla Merkely; Andrea Varga; Gyula Gyebnár; Ferenc Imre Suhai; Anikó Ilona Nagy; Lajos Rudolf Kozák; Csenge Ágnes Póka; Mirjam Franciska Turáni; Sarolta Borzsák; Astrid Apor; Andrea Bartykowszki; Bálint Szilveszter; Márton Kolossváry Journal: Neuroradiology Date: 2022-08-01 Impact factor: 2.995
Authors: Paul Toon Lim Chiam; Nien Shen Chan; Yean Teng Lim; Choon Pin Lim; Dinesh Nair; Tai Tian Lim; Chao Yang Soon; Brian Chung Hoe Khoo; Jimmy Lim; Kok Soon Tan; Leslie Lam; Peter Yan; Yau Wei Ooi; Mei Sian Chong Journal: Singapore Med J Date: 2022-02-24 Impact factor: 3.331
Authors: Alexander Ghanem; Jonas Dörner; Leonie Schulze-Hagen; Andreas Müller; Marius Wilsing; Jan-Malte Sinning; Julian Lütkens; Christian Frerker; Karl-Heinz Kuck; Ingo Gräff; Hans Schild; Nikos Werner; Eberhard Grube; Georg Nickenig Journal: PLoS One Date: 2017-01-05 Impact factor: 3.240